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Abstract
Background: Despite significant changes in the clinical and histologic diagnosis of prostate cancer, the Gleason
grading system remains one of the most powerful prognostic predictors in prostate cancer. The correct diagnosis
and grading of prostate cancer is crucial for a patient’s prognosis and therapeutic options. However, this system has
undergone significant revisions and continues to have deficiencies that can potentially impact patient care.
Main Body: We describe the current state of grading prostate cancer, focusing on the current guidelines for the
Gleason grading system and recent changes from the 2014 International Society of Urological Pathology Consensus
Conference on Gleason Grading of Prostatic Carcinoma. We also explore the limitations of the current Gleason
grading system and present a validated alternative to the Gleason score. The new grading system initially described
in 2013 in a study from Johns Hopkins Hospital and then validated in a multi-institutional study, includes five
distinct Grade Groups based on the modified Gleason score groups. Grade Group 1 = Gleason score ≤6, Grade
Group 2 = Gleason score 3 + 4 = 7, Grade Group 3 = Gleason score 4 + 3 = 7, Grade Group 4 = Gleason score 8,
Grade Group 5 = Gleason scores 9 and 10.
Conclusion: As this new grading system is simpler and more accurately reflects prostate cancer biology, it is
recommended by the World Health Organization (WHO) to be used in conjunction with Gleason grading.
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Background
The Gleason grading system is based on a study from
1959 through 1964 by the Veteran’s Affairs Cooperative
Research Group (VACURG), which enrolled 270 men
with prostate cancer [1]. Dr. Donald Gleason, the Chief
of Pathology at the Veteran’s Hospital in Minnesota, cre-
ated a grading system for prostate cancer based on its
different histologic patterns. As most of the tumors typ-
ically had two histologic patterns, a score was created
that added the two most common grade patterns in a
tumor, with scores ranging from 2 to 10. The study dem-
onstrated a progressive increase in cancer specific mor-
tality with an increase in score [1]. For ease of grading,
the five prognostic patterns were demonstrated by a
simple diagram drawn by Dr. Gleason (Fig. 1).
Despite significant changes in the clinical and histo-
logic diagnosis of prostate cancer, the Gleason grading
system remains one of the most powerful prognostic
predictors in prostate cancer. However, this system has
undergone significant revisions and continues to have
deficiencies that can potentially impact patient care.
Herein we describe the current state of grading prostate
cancer, focusing on the current guidelines for the Glea-
son grading system and recent changes from the 2014
International Society of Urological Pathology (ISUP)
Consensus Conference on Gleason Grading of Prostatic
Carcinoma [2, 3]. We also explore the limitations of the
current Gleason grading system and present a validated
alternative to the Gleason score [4, 5].
Main text
Gleason grading
Gleason grading of prostatic adenocarcinoma can typic-
ally be performed using the 4x objective, although there
may be certain instances (ie. back-to-back glands vs.
fused glands) that require higher magnification at 10x
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objective. Gleason scores should be reported as a math-
ematical equation, for example, Gleason score 4 + 3 = 7,
so as to avoid ambiguity.
The current application of the Gleason grading system
is significantly different from the original version. Glea-
son patterns 1 and 2 (Gleason scores 2–5) should no
longer be assigned on needle core biopsy. This is be-
cause of poor reproducibility and poor correlation with
radical prostatectomy grade [6, 7]. In addition, a diagno-
sis of Gleason score of 2–5 is misleading for both clini-
cians and patients as nearly all cases show higher grade
at resection [6, 7]. The original study by Gleason did not
benefit from the use of immunohistochemistry and it is
likely that Gleason’s original 1 + 1 = 2 adenocarcinomas
were in fact adenosis. In addition, with the current
changes in Gleason grading, nearly all the previously
considered Gleason pattern 2 adenocarcinomas are now
classified as Gleason grade 3. Over the last decade there
has been a dramatic decrease in the current incidence of
pathologists diagnosing Gleason score 2–4 compared to
22.3 % of the biopsies in 1994 [8, 9].
Gleason pattern 3 consists of well-formed, individual
glands of various sizes including branching glands
(Fig. 2a). The glands should form discrete units, such
that one could draw a circle around each individual
gland. Small glands are acceptable for Gleason grade 3
as long as they are well formed and not fused. Gleason
pattern 3 should typically be diagnosed at low magnifica-
tion (4x objective). This is to prevent over-grading a
tumor based on a few poorly formed glands at high
power, which could represent tangential sectioning of
small well-formed glands. Perineural invasion and mu-
cinous fibroplasia (collagenous micronodules) can also
cause glands that appear more complex, and one should
be cautious in assigning Gleason pattern 4 in these areas
unless overtly cribriform. Biopsies with only a small
focus of Gleason pattern 3 can still be assigned a pri-
mary and secondary pattern resulting in a Gleason score
3 + 3 = 6, since these biopsies are likely to show Gleason
score 3 + 3 = 6 on radical prostatectomy [8].
Gleason pattern 4 includes poorly-formed, fused, and
cribriform glands (Fig. 2b-f ). Glomeruloid morphology is
characterized by dilated glands containing intraluminal
cribriform structures with a single point of attachment,
resembling a renal glomerulus [10] (Fig. 2e). There was
no consensus as to how to grade this particular histo-
logic variant in the 2005 ISUP grading conference. In
2009, Lotan et al. demonstrated that 84 % of cases with
glomeruloid glands were associated with Gleason pattern
4 or higher cancer [11]. This same study documented
that there were often transitions between small and large
glomerulations and cribriform glands. At the 2014 re-
cent ISUP grading conference, it was determined that
glomeruloid morphology should be considered Gleason
pattern 4 [3]. Cribriform prostate cancer has a spectrum
of differentiation. Cribriform glands are classically
thought of as having well-formed, punched-out, lumens
(Fig. 2c). However, less differentiated examples can have
lumina that are not as open but are still considered pat-
tern 4. The original Gleason grading system included
round and regular cribriform glands as Gleason pattern
3, whereas in pattern 4 they were more irregular with
ragged edges (Fig. 1). Studies have shown that cases with
cribriform glands previous considered pattern 3 would
uniformly be considered grade 4 by today’s standards
[12, 13]. In addition, studies have shown that cribriform
pattern in radical prostatectomy specimens are associ-
ated with biochemical recurrence, extraprostatic exten-
sion, positive surgical margins, distant metastases, and
cancer-specific mortality [14–18]. For these reasons, all
cribriform glands should be assigned Gleason pattern 4
[3]. The consequence of cribriform glands and poorly-
formed glands being considered as Gleason pattern 4
when they were previously grades as Gleason pattern 3
is that there is an increase in Gleason score 7 tumors as
well as a better prognosis for current Gleason score 6
tumors compared to their historic counterparts. These
modifications have led to a better correlation between
the Gleason grade found on biopsy and that found on
Fig. 1 The original Gleason Grading system diagram
Gordetsky and Epstein Diagnostic Pathology  (2016) 11:25 Page 2 of 8
radical prostatectomy. They have also shown improved
prediction of prostatectomy stage, margins, tumor vol-
ume, and biochemical recurrence [19–23].
Gleason pattern 5 consists of sheets of tumor, individ-
ual cells, and cords of cells (Fig. 3a-d). Solid nests of
cells with vague microacinar or only occasional gland
space formation are also considered Gleason pattern 5.
A more uncommon pattern 5 morphology is comedone-
crosis within solid nests or cribriform glands. It is im-
portant to distinguish intraluminal eosinophilic
secretions from true necrosis. Intraductal carcinoma
(discussed under histologic variants) can mimic Gleason
pattern 5 [24, 25]. Gleason pattern 5 is frequently under-
graded by pathologists [26].
Histologic variants
Intraductal carcinoma (IDC) (Fig. 3e) is the spread of
adenocarcinoma within prostatic ducts and in most
cases is considered to be extension of high grade in-
vasive tumor into ducts [12, 27]. IDC on needle core
biopsy has been shown to be associated with high-
grade tumor and high stage disease on radical prosta-
tectomy, metastatic disease, and decreased cancer-free
survival [24, 25, 28, 29]. In addition, IDC is an inde-
pendent prognosticator of early biochemical recur-
rence and metastases in patients treated with
radiation therapy [30]. However, IDC is occasionally a
precursor lesion rather than extension of invasive car-
cinoma into ducts and may be present at radical
prostatectomy either without invasive carcinoma or
with Gleason score 3 + 3 = 6 cancer [29, 31]. In these
cases, if IDC had been assigned a high grade on bi-
opsy it would have been misleading, as pure IDC at
radical prostatectomy is thought to have no risk of
disease recurrence [29, 25]. In biopsies where IDC is
associated with obvious high-grade invasive tumor,
immunohistochemistry is not needed for the diagnosis
of IDC. Immunohistochemistry should be used in
cases where the results of the studies would change
the case’s overall grade. At the recent 2014 ISUP
grading conference it was recommended that IDC not
be graded [3]. However, a comment should be added
Fig. 2 a Gleason score 3 + 3 = 6 (Grade Group 1). b Gleason score 3 + 4 = 7 (Grade Group 2) with minor component of cribriform glands. c
Gleason score 4 + 4 = 8 (Grade Group 4) with irregular cribriform glands. d Gleason score 4 + 4 = 8 (Grade Group 4) with fused glands with
cytoplasmic vacuoles. e Gleason score 4 + 4 = 8 (Grade Group 4) with glomeruloid glands. f Gleason score 4 + 4 = 8 (Grade Group 4) with
poorly-formed glands
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to the pathology report that this finding is usually as-
sociated with high-grade invasive prostate cancer.
Mucinous adenocarcinoma (Fig. 3f) is a variant of pros-
tatic adenocarcinoma where the infiltrative glands have
abundant extracellular mucin. There was no consensus as
to how to grade this particular histologic variant in the
2005 ISUP grading meeting as the clinical behavior of this
entity was unclear. It was previously thought that this
tumor behaved as Gleason grade 4 and some proposed to
consider all mucinous tumors as Gleason grade 4 [2]. Two
studies have since been published that showed mucinous
adenocarcinoma of the prostate treated by radical prosta-
tectomy is not more aggressive than non-mucinous pros-
tate cancer [32, 33]. Thus the consensus in the 2014 ISUP
grading meeting was to grade this variant based on its
underlying growth pattern [3].
Grading of multiple cores with cancer
In the United States it is standard of care for urologists
to perform a 10–12 core biopsy. In some cases, multiple
cores may be positive for cancer, with different cores
having a different Gleason grade. As long as the cores
are submitted in separate containers or designated by lo-
cation (for example by ink) the pathologist should report
the grades of each core separately. In cases where differ-
ent cores are present within the same specimen con-
tainer without a designation as to location, there is no
consensus whether the individual cores are still given a
grade or whether there is only 1 grade given to the part,
averaging the grades on different cores. Several studies
have demonstrated that in cases with different cores hav-
ing different grades, the highest Gleason score on a
given core correlates better with stage and Gleason score
at radical prostatectomy than the average or most fre-
quent grade amongst the cores [34–37]. If multiple frag-
mented cores are in a specimen container, only an
overall Gleason score for that part can be reported. In
other countries, there is a tendency to also derive an
overall or global grade at the end of the case. An argu-
ment against giving an overall (global) grade is that the
Fig. 3 a Gleason score 5 + 5 = 10 (Grade Group 5) with solid sheets of cells. b Gleason score 5 + 5 = 10 (Grade Group 5) with cords of cells. c
Gleason score 5 + 5 = 10 (Grade Group 5) with individual cells. d Gleason score 5 + 4 = 9 (Grade Group 5) with cribriform glands, some with
necrosis. e Intraductal carcinoma with necrosis (left), surrounded by basal cells highlighted by p63 and high molecular weight cytokeratin (right)
and positive for racemase. f Mucinous adenocarcinoma Gleason score 3 + 4 = 7 (Grade Group 2) with individual well-formed glands and minor
component of cribriform glands floating in extracellular mucin
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pathologist cannot know whether the cancer on different
cores represents the same or multifocal tumor. The ur-
ologist, who can factor in the findings on imaging stud-
ies, is better equipped to determine what the overall
grade might be in the setting of multifocal tumor. How-
ever, in general, the highest grade per core is used to
predict prognosis and determine therapy.
Tertiary grade on needle core biopsy
In contrast to the original Gleason grading system, it is
now recommended that on a needle core biopsy both
the most common and highest grade are added together
for the Gleason score [2]. For example, if there is 60 %
Gleason pattern 3, 35 % Gleason pattern 4, and 5 %
Gleason pattern 5, the Gleason score would be 3 + 5 = 8.
Needle core biopsy is an imperfect, non-targeted, ran-
dom sampling of the prostate gland. Thus any amount
of high-grade tumor sampled on needle biopsy most
likely indicates a more significant amount of high-grade
tumor within the prostate. In all specimens, in the set-
ting of high-grade cancer, one should not report a lower
grade if it occupies less than 5 % of the total tumor. For
example, if there is 98 % Gleason pattern 4 and 2 %
Gleason pattern 3, the Gleason score would be reported
as 4 + 4 = 8 [2].
Grading on radical prostatectomy
It was recommended at the 2005 ISUP grading confer-
ence that each dominant tumor nodule should be given
a Gleason Score [2]. This issue becomes important when
separate nodules have significantly different Gleason
grades. For example, a case might have a nodule of Glea-
son score 4 + 4 = 8 within the peripheral zone and a lar-
ger nodule of Gleason score 3 + 3 = 6 within the
transition zone. The patient’s clinical prognosis is going
to be dictated by the higher grade tumor, whereas giving
an overall Gleason score of 3 + 4 = 7 will undergrade the
tumor and be misleading. In order to grade separate
dominant tumor nodules, radical prostatectomy speci-
mens should be processed in an organized fashion. This
does not necessarily require embedding the entire speci-
men. However, it does require that the prostate be sub-
mitted in a fashion that maintains orientation in order
to distinguish between different tumor nodules [38–40].
In most prostates there is one or two dominant nodules.
The dominant nodule is typically the largest tumor and
is associated with the highest stage and highest grade.
Small foci of Gleason score 6 cancer that often co-exist
with dominant tumor nodules do not need to be re-
ported. Tertiary grades are provided only in radical pros-
tatectomy specimens, when in a nodule there is a third
component of a Gleason pattern higher than the primary
and secondary patterns, and where the tertiary compo-
nent is <5 % of the whole tumor. When the 3rd most
common component is the highest grade and occupies
>5 % of the tumor, it is typically recorded as the second-
ary pattern. So 50 % pattern 4, 30 % pattern 3, and 20 %
pattern 5, would be reported as 4 + 5 = 9. Tertiary Glea-
son patterns are in general associated with higher patho-
logical stage and biochemical recurrence as compared to
the same Gleason score cancers without tertiary patterns
[41–43].
Clinical risk stratification
Gleason score continues to be the single most powerful
predictor of prostate cancer prognosis and directs clinical
management. Various scores have been grouped together
based on the assumption that they have a similar progno-
sis. Urologists use Gleason score along with other clinical
variables to create risk stratification for patient manage-
ment. There is considerable diversity in the literature re-
garding Gleason score grouping including: 2–4, 5–7, 8–
10; 2–6, 7, 8–10; and 2–6, 7–10 [44–46]. The most com-
mon risk stratification for prostate cancer is the National
Comprehensive Cancer Network (NCCN) and D’Amico
classification system [47]. It stratifies prostate cancer
based on PSA, clinical stage, and biopsy score into low
risk (2–6), intermediate risk (7), and high risk (8–10),
where both 3 + 4 = 7 and 4 + 3 = 7 is considered the same
within the intermediate risk group. Similarly, Gleason
score 8 is not distinguished from Gleason score 9–10 in
the high risk group. Several studies have shown an adverse
prognosis associated with Gleason grade 5, especially as it
applies to radiation therapy [48–52].
Limitations of the gleason grading system
Although current revisions have improved the Gleason
grading system, it continues to have limitations. Recent
modifications have made the Gleason grading system
much more complex than its original version. This com-
plexity can be confusing for patients and clinicians.
Gleason score 6 is now recommended as the lowest
grade to be assigned on prostate biopsy. This is counter-
intuitive in that the Gleason scale ranges from 2 to 10.
Patients may assume that a diagnosis of Gleason score 6
on biopsy means their tumor is in the mid-range of ag-
gressiveness rather than having the best prognosis. In
addition, many former Gleason score 6 tumors are now
reclassified as Gleason score 7 in the modified system.
Modern Gleason score 6 tumors have a much better
prognosis than reported in the older literature. Studies
have shown that virtually no pure Gleason score 6 tu-
mors are associated with disease recurrence after radical
prostatectomy and pure Gleason 6 cancer at radical
prostatectomy lacks the potential for lymph node metas-
tases [4, 53]. Another problem in the modern Gleason
grading system is the lumping of Gleason score 7, as
noted above in the NCCN Risk Classification System.
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Whereas many clinicians consider Gleason score 7 on
biopsy to be intermediate risk, multiple studies have
shown that Gleason score 4 + 3 = 7 demonstrates worse
pathological stage and biochemical recurrence rates than
3 + 4 = 7 [54–56].
A new grading system
In 2013, a new grading system was proposed by the
group from Johns Hopkins Hospital [4]. The grading
system includes five distinct Grade Groups based on the
modified Gleason score groups. Grade Group 1 = Glea-
son score ≤ 6, Grade Group 2 = Gleason score 3 + 4 = 7,
Grade Group 3 = Gleason score 4 + 3 = 7, Grade Group
4 = Gleason score 4 + 4 = 8, Grade Group 5 = Gleason
scores 9 and 10. A multi-institutional study including
Johns Hopkins Hospital, Memorial Sloan-Kettering Can-
cer Center (MSKCC), University of Pittsburgh, Cleve-
land Clinic, and the Karolinska Institute validated the
new grading system on 20,845 radical prostatectomy
cases with a mean follow-up period, without progres-
sion, of 3 years. [5]. The 5-year biochemical risk-free
survivals for the 5 Grade Groups based on radical pros-
tatectomy grade were 96, 88, 63, 48, and 26 %, respect-
ively. These Grade Groups were shown to be more
accurate in predicting progression than the Gleason risk
stratification groups (≤6, 7, 8–10). The Grade Groups
showed similar prognostic curves on biopsy in men
treated with radiation +/− hormonal therapy as well as
radical prostatectomy. Using this new system, patients
could be reassured that they have a Grade Group 1
tumor on biopsy that is the lowest grade tumor possible,
which in most cases can be followed with active surveil-
lance. Follow-up is still needed as there is unsampled
higher grade cancer in approximately 20 % of cases [57].
As this new grading system is simpler and more accur-
ately reflects prostate cancer biology, we recommend
using it in conjunction with Gleason grading. For ex-
ample: Gleason score 3 + 3 = 6 (Grade Group 1). This
new grading system has been accepted by the World
Health Organization (WHO) for the 2016 edition of
Pathology and Genetics: Tumours of the Urinary System
and Male Genital Organs [3].
Conclusions
Gleason score continues to be the single most powerful
predictor of prostate cancer prognosis and plays a sig-
nificant role in clinical management. The correct diag-
nosis and grading of prostate cancer is crucial for a
patient’s prognosis and therapeutic options. The 2005
and 2014 ISUP grading consensus conferences have im-
proved the overall Gleason grading system. However,
this system continues to have limitations which a new
prostate cancer grading system improves upon.




Availability of data and materials
Not applicable.
Abbreviations
IDC: Intraductal carcinoma; ISUP: International Society of Urological
Pathology; NCCN: National Comprehensive Cancer Network;
VACURG: Veteran’s Affairs Cooperative Research Group.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
JG drafted the manuscript and contributed photos. JE edited the manuscript
and contributed photos. Both authors read and approved the final
manuscript.
Author details
1Department of Pathology, University of Alabama at Birmingham,
Birmingham, AL, USA. 2Department of Urology, University of Alabama at
Birmingham, Birmingham, AL, USA. 3Department of Pathology, The Johns
Hopkins Hospital, The Weinberg Building Room 2242. 401 North Broadway
St., Baltimore, MD 21231, USA. 4Department of Urology, The Johns Hopkins
Hospital, Baltimore, MD, USA.
Received: 15 October 2015 Accepted: 26 February 2016
References
1. Gleason DF, Mellinger GT. Prediction of prognosis for prostatic
adenocarcinoma by combined histological grading and clinical staging. J
Urol. 1974;111:58–64.
2. Epstein JI, Allsbrook Jr WC, Amin MB, Egevad LL. ISUP Grading Committee.
The 2005 International Society of Urological Pathology(ISUP) Consensus
Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol.
2005;29:1228–42.
3. Epstein JI, Egevad L, Amin MB, Delahunt B, Srigley JR, Humphrey PA. The
2014 International Society of Urological Pathology (ISUP) Consensus
Conference on Gleason Grading of Prostatic Carcinoma: definition of
grading patterns and proposal for a new grading system. Am J Surg Pathol.
2016;40(2):244–52.
4. Pierorazio PM, Walsh PC, Partin AW, Epstein JI. Prognostic Gleason grade
grouping: data based on the modified Gleason scoring sys- tem. BJU Int.
2013;111:753–60.
5. Epstein JI, Zelefsky MJ, Sjoberg DD, Nelson JB, Egevad L, Magi-Galluzzi C,
Vickers AJ, Parwani AV, Reuter VE, Fine SW, Eastham JA, Wiklund P, Han M,
Reddy CA, Ciezki JP, Nyberg T, Klein EA. A Contemporary Prostate Cancer
Grading System: A Validated Alternative to the Gleason Score. Eur Urol.
2016;69(3):428-35.
6. Epstein JI. Gleason score 2–4 adenocarcinoma of the prostate on needle
biopsy: a diagnosis that should not be made. Am J Surg Pathol. 2000;24(4):
477–8. Review.
7. Cury J, Coelho RF, Srougi M. Well-differentiated prostate cancer in core
biopsy specimens may be associated with extraprostatic disease. Sao Paulo
Med J. 2008;126(2):119–22.
8. Steinberg DM, Sauvageot J, Piantadosi S, Epstein JI. Correlation of prostate
needle biopsy and radical prostatectomy Gleason grade in academic and
community settings. Am J Surg Pathol. 1997;21(5):566–76.
9. Fine SW, Epstein JI. A contemporary study correlating prostate needle
biopsy and radical prostatectomy Gleason score. J Urol. 2008;179(4):1335–8.
discussion 1338–9. 8.
10. Baisden BL, Kahane H, Epstein JI. Perineural invasion, mucinous fibroplasia,
and glomerulations: diagnostic features of limited cancer on prostate
needle biopsy. Am J Surg Pathol. 1999;23(8):918–24.
Gordetsky and Epstein Diagnostic Pathology  (2016) 11:25 Page 6 of 8
11. Lotan TL, Epstein JI. Gleason grading of prostatic adenocarcinoma with
glomeruloid features on needle biopsy. Hum Pathol. 2009;40:471–7.
12. McNeal JE, Yemoto CE. Spread of adenocarcinoma within prostatic ducts
and acini. morphologic and clinical correlations. Am J Surg Pathol. 1996;20:
802–14.
13. Ross HM, Kryvenko ON, Cowan JE, Simko JP, Wheeler TM, Epstein JI. Do
adenocarcinomas of the prostate with Gleason score (GS) <6 have the
potential to metastasize to lymph nodes? Am J Surg Pathol. 2012;36:1346–52.
14. Iczkowski KA, Torkko KC, Kotnis GR, et al. Digital quantification of five high-
grade prostate cancer patterns, including the cribriform pattern, and their
association with adverse outcome. Am J Clin Pathol. 2011;136:98–107.
15. Kir G, Sarbay BC, Gumus E, Topal CS. The association of the cribriform
pattern with outcome for prostatic adenocarcinomas. Pathol Res Pract.
2014;210:640–4.
16. Sarbay BC, Kir G, Topal CS, Gumus E. Significance of the cribriform pattern in
prostatic adenocarcinomas. Pathol Res Pract. 2014;210:554–7.
17. Trudel D, Downes MR, Sykes J, Kron KJ, Trachtenberg J, van der Kwast TH.
Prognostic impact of intraductal carcinoma and large cribriform carcinoma
architecture after prostatectomy in a contemporary cohort. Eur J Cancer.
2014;50:1610–6.
18. Kweldam CF, Wildhagen MF, Steyerberg EW, Bangma CH, van der Kwast TH,
van Leenders GJ. Cribriform growth is highly predictive for postoperative
metastasis and disease-specific death in gleason score 7 prostate cancer.
Mod Pathol. 2015;28:457–64.
19. Billis A, Guimaraes MS, Freitas LL, et al. The impact of the 2005 international
society of urological pathology consensus conference on standard Gleason
grading of prostatic carcinoma in needle biopsies. J Urol. 2008;180:548–52.
discussion 552–3.
20. Helpap B, Egevad L. The significance of modified Gleason grading of
prostatic carcinoma in biopsy and radical prostatectomy specimens.
Virchows Arch. 2006;449:622–7.
21. Ozok HU, Sagnak L, Tuygun C, et al. Will the modification of the Gleason
grading system affect the urology practice? Int J Surg Pathol. 2010;18:248–54.
22. Tsivian M, Sun L, Mouraviev V, et al. Changes in Gleason score grading and
their effect in predicting outcome after radical prostatectomy. Urology.
2009;74:1090–3.
23. Uemura H, Hoshino K, Sasaki T, et al. Usefulness of the 2005 International
Society of Urologic Pathology Gleason grading system in prostate biopsy
and radical prostatectomy specimens. BJU Int. 2009;103:1190–4.
24. Guo CC, Epstein JI. Intraductal carcinoma of the prostate on needle biopsy:
Histologic features and clinical significance. Mod Pathol. 2006;19(12):1528–35.
25. Robinson BD, Epstein JI. Intraductal carcinoma of the prostate without
invasive carcinoma on needle biopsy: emphasis on radical prostatectomy
findings. J Urol. 2010;184(4):1328–33.
26. Fajardo DA, Miyamoto H, Miller JS, Lee TK, Epstein JI. Identification of Gleason
pattern 5 on prostatic needle core biopsy: frequency of underdiagnosis and
relation to morphology. Am J Surg Pathol. 2011;35(11):1706–11.
27. Kovi J, Jackson MA, Heshmat MY. Ductal spread in prostatic carcinoma.
Cancer. 1985;56:1566–73.
28. Zhao T, Liao B, Yao J, et al. Is there any prognostic impact of intraductal
carcinoma of prostate in initial diagnosed aggressively metastatic prostate
cancer? Prostate. 2015;75:225–32.
29. Watts K, Li J, Magi-Galluzzi C, Zhou M. Incidence and
clinicopathological characteristics of intraductal carcinoma detected in
prostate biopsies: A prospective cohort study. Histopathology. 2013;63:
574–9.
30. Van der Kwast T, Al Daoud N, Collette L, et al. Biopsy diagnosis of
intraductal carcinoma is prognostic in intermediate and high risk prostate
cancer patients treated by radiotherapy. Eur J Cancer. 2012;48:1318–25.
31. Khani F, Epstein JI. Prostate Biopsy Specimens with Gleason 3 + 3 = 6
and Intraductal Carcinoma: Radical Prostatectomy Findings and Clinical
Outcomes. Am J Surg Pathol. 2015;39(10):1383–9.
32. Lane BR, Magi-Galluzzi C, Reuther AM, Levin HS, Zhou M, Klein EA. Mucinous
adenocarcinoma of the prostate does not confer poor prognosis. Urology. 2006;
68:825–30.
33. Osunkoya AO, Nielsen ME, Epstein JI. Prognosis of mucinous adenocarcinoma
of the prostate treated by radical prostatectomy: A study of 47 cases. Am J
Surg Pathol. 2008;32:468–72.
34. Kunz Jr GM, Epstein JI. Should each core with prostate cancer be assigned a
separate gleason score? Hum Pathol. 2003;34(9):911–4.
35. Park HK, Choe G, Byun SS, Lee HW, Lee SE, Lee E. Evaluation of concordance of
Gleason score between prostatectomy and biopsies that show more than two
different Gleason scores in positive cores. Urology. 2006;67(1):110–4.
36. Poulos CK, Daggy JK, Cheng L. Preoperative prediction of Gleason
grade in radical prostatectomy specimens: the influence of different
Gleason grades from multiple positive biopsy sites. Mod Pathol. 2005;
18(2):228–34.
37. Kunju LP, Daignault S, Wei JT, Shah RB. Multiple prostate cancer cores with
different Gleason grades submitted in the same specimen container
without specific site designation: should each core be assigned an
individual Gleason score? Hum Pathol. 2009;40(4):558–64.
38. Cohen MB, Soloway MS, Murphy WM. Sampling of radical prostatectomy
specimens. How much is adequate? Am J Clin Pathol. 1994;101(3):250–2.
39. Hall GS, Kramer CE, Epstein JI. Evaluation of radical prostatectomy
specimens. A comparative analysis of sampling methods. Am J Surg Pathol.
1992;16(4):315–24.
40. Sehdev AE, Pan CC, Epstein JI. Comparative analysis of sampling methods
for grossing radical prostatectomy specimens performed for nonpalpable
(stage T1c) prostatic adenocarcinoma. Hum Pathol. 2001;32(5):494–9.
41. Turker P, Bas E, Bozkurt S, Günlüsoy B, Sezgin A, Postacı H, et al. Presence of
high grade tertiary Gleason pattern upgrades the Gleason sum score and is
inversely associated with biochemical recurrence-free survival. Urol Oncol.
2013;31(1):93–8.
42. Servoll E, Saeter T, Vlatkovic L, Nesland J, Waaler G, Beisland HO. Does a
tertiary Gleason pattern 4 or 5 influence the risk of biochemical relapse after
radical prostatectomy for clinically localized prostate cancer? Scand J Urol
Nephrol. 2010;44(4):217–22.
43. Whittemore DE, Hick EJ, Carter MR, Moul JW, Miranda-Sousa AJ, Sexton WJ.
Significance of tertiary Gleason pattern 5 in Gleason score 7 radical
prostatectomy specimens. J Urol. 2008;179(2):516–22. discussion 522.
44. Resnick MJ, Koyama T, Fan KH, et al. Long-term functional outcomes after
treatment for localized prostate cancer. N Engl J Med. 2013;368:436–45.
45. Wilt TJ, Brawer MK, Jones KM, et al. Radical prostatectomy versus
observation for localized prostate cancer. N Engl J Med. 2012;367:203–13.
46. Bill-Axelson A, Holmberg L, Garmo H, et al. Radical prostatectomy or
watchful waiting in early prostate cancer. N Engl J Med. 2014;370:932–42.
47. D’Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome
after radical prostatectomy, external beam radiation ther- apy, or
interstitial radiation therapy for clinically localized prostate cancer.
JAMA. 1998;280:969–74.
48. Sabolch A, Feng FY, Daignault-Newton S, et al. Gleason pattern 5 is the
greatest risk factor for clinical failure and death from prostate cancer after
dose-escalated radiation therapy and hormonal ablation. Int J Radiat Oncol
Biol Phys. 2011;81:e351–60.
49 Stenmark MH, Blas K, Halverson S, Sandler HM, Feng FY, Hamstra DA.
Continued benefit to androgen deprivation therapy for prostate cancer
patients treated with dose-escalated radiation therapy across multiple
definitions of high-risk disease. Int J Radiat Oncol Biol Phys. 2011;81:
e335–44.
50. Stock RG, Cesaretti JA, Stone NN. Disease-specific survival following the
brachytherapy management of prostate cancer. Int J Radiat Oncol Biol Phys.
2006;64:810–6.
51. Sylvester JE, Grimm PD, Wong J, Galbreath RW, Merrick G, Blasko JC.
Fifteen-year biochemical relapse-free survival, cause-specific survival, and
overall survival following I(125) prostate brachytherapy in clinically
localized prostate cancer: Seattle experience. Int J Radiat Oncol Biol
Phys. 2011;81:376–81.
52. Stone NN, Stone MM, Rosenstein BS, Unger P, Stock RG. Influence of
pretreatment and treatment factors on intermediate to long-term
outcome after prostate brachytherapy. J Urol. 2011;185:495–500.
53. Miyamoto H, Hernandez DJ, Epstein JI. A pathological reassessment of
organ-confined, Gleason score 6 prostatic adenocarcinomas that
progress after radical prostatectomy. Hum Pathol. 2009;40:1693–8.
54. Burdick MJ, Reddy CA, Ulchaker J, et al. Comparison of biochemical relapse-
free survival between primary Gleason score 3 and primary Gleason score 4
for biopsy Gleason score 7 prostate cancer. Int J Radiat Oncol Biol Phys.
2009;73:1439–45.
55. Chan TY, Partin AW, Walsh PC, Epstein JI. Prognostic significance of Gleason
score 3 + 4 versus Gleason score 4 + 3 tumor at radical prostatectomy.
Urology. 2000;56:823–7.
Gordetsky and Epstein Diagnostic Pathology  (2016) 11:25 Page 7 of 8
56. Kang DE, Fitzsimons NJ, Presti Jr JC, et al. Risk stratification of men with
Gleason score 7 to 10 tumors by primary and secondary Gleason score:
results from the SEARCH database. Urology. 2007;70:277–82.
57. Epstein JI, Feng Z, Trock BJ, Pierorazio PM. Upgrading and downgrading of
prostate cancer from biopsy to radical prostatectomy: Incidence and
predictive factors using the modified Gleason grading system and factoring
in tertiary grades. Eur Urol. 2012;61:1019–24.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Gordetsky and Epstein Diagnostic Pathology  (2016) 11:25 Page 8 of 8
